A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, national multicenter clinical study ，which is designed to compare
the efficacy of the safety and efficacy of treatment every 3 weeks or 6 weeks in
(Non-small-cell-cell cancer, NSCLC) subjects without systematic treatment， who used
Pembrolizumab after 6 cycles of combined chemotherapy， estimated with stable efficacy (CR,
PR, and SSD) .
In this study, subjects will be randomly assigned to the following two groups according to a
1:1 ratio:
(A) Standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of
2 years of follow-up and follow-up for 1 year; (B) Improvement maintenance programme group,
pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;
Phase:
N/A
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators:
Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine Beijing Sino-Japan Friendship Hospital Changhai Hospital of the Second Military Medical University First Hospital of China Medical University Guangzhou Medical University Jiangsu People's Hospital Qilu Hospital Affiliated to Shandong University Qilu Hospital of Shandong University Southern Medical University, China The Second Affiliated Hospital of Fujian Medical University The Second Affiliated Hospital of the Army Medical University (the Third Military Medical University) - Xinqiao Hospital Tongji Hospital Tongji Hospital Affiliated to Huazhong University of science and technology West China Hospital Affiliated to West China Medical University Xiangya Hospital Affiliated to Central South University Xijing Hospital Affiliated to the Fourth Military Medical University Zunyi Medical University Affiliated Hospital